Chronic lung disease of prematurity, often called bronchopulmonary dysplasia, is a chronic respiratory condition in preterm infants caused by disrupted lung development and injury from prematurity-related respiratory support.
The European Commission approved Enflonsia for prevention of RSV lower respiratory tract disease in infants during their first RSV season. Merck also reported new Phase 3 SMART data showing generally consistent second-season safety in high-risk children under 2 years old.
Merck announced positive second RSV season findings from the Phase 3 SMART trial evaluating ENFLONSIA (clesrovimab) in infants and children under 2 years at increased risk for severe RSV disease, showing consistent safety and antibody levels similar to healthy infants.
